Håkan Mellstedt

Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.

M. Wadhwa, C. Bird, R. Thorpe, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.

R Thorpe, M Wadhwa, M. Wadhwa, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.

J. Fagerberg, H. Wigzell, H. Mellstedt, 1995, Cancer research.

Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity

H. Mellstedt, P. Wersäll, G. Masucci, 2004, Cancer Immunology, Immunotherapy.

Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).

C. Lindemalm, G. Masucci, H. Mellstedt, 1988, Hybridoma.

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma

P. Wersäll, H. Mellstedt, P. Biberfeld, 1997, Cancer Immunology, Immunotherapy.

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma

J. Fagerberg, J. Shetye, B. Nilsson, 1999, Cancer Immunology, Immunotherapy.